EI
NBIX icon

EAM Investors’s Neurocrine Biosciences NBIX Stock Holding History

EAM Investors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,187
Closed -$1.58M – 323
2022
Q4 		$1.58M Sell
13,187
-166
-1% -$19.4K 0.33% 136
2022
Q3 		$1.42M Buy
13,353
+2,041
+18% +$207K 0.31% 140
2022
Q2 		$1.1M Buy
+11,312
New +$1.04M 0.27% 177
2018
Q2 		– Sell
-41,529
Closed -$3.44M – 331
2018
Q1 		$3.44M Buy
41,529
+3,249
+8% +$274K 0.57% 44
2017
Q4 		$2.97M Sell
38,280
-493
-1% -$33.6K 0.53% 51
2017
Q3 		$2.38M Buy
+38,773
New +$2.05M 0.32% 140
2016
Q3 		– Sell
-55,895
Closed -$2.54M – 338
2016
Q2 		$2.54M Sell
55,895
-25,489
-31% -$1.17M 0.38% 133
2016
Q1 		$3.22M Buy
81,384
+5,171
+7% +$205K 0.5% 49
2015
Q4 		$4.31M Buy
76,213
+18,502
+32% +$940K 0.56% 30
2015
Q3 		$2.3M Sell
57,711
-13,421
-19% -$649K 0.36% 125
2015
Q2 		$3.4M Buy
+71,132
New +$3.02M 0.4% 90
2013
Q3 		– Sell
-180,478
Closed -$2.42M – 350
2013
Q2 		$2.42M Buy
+180,478
New +$2.22M 0.52% 37

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EAM Investors's NBIX Position: Q1 2023 in Review

EAM Investors sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 13,187 shares — an estimated $1.58M sold.

EAM Investors first reported a position in NBIX in Q2 2013 and held it in 12 quarters. The position peaked at $4.31M in Q4 2015. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

  • EAM Investors reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
  • EAM Investors sold 13,187 Neurocrine Biosciences shares in Q1 2023, an estimated $1.58M.
  • EAM Investors first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 12 quarters.
  • EAM Investors's Neurocrine Biosciences position peaked at $4.31M in Q4 2015.
  • 486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on EAM Investors's 13F filing for Q1 2023, filed 15 May 2023.